|
LIPID LOWERING DOSE OF NICOTINIC ACID MAY CAUSE RHABDOMYOLYSIS & MYOPATHY ON CO-ADMINISTRATION
|
POTENTIAL FOR LOSS OF GLYCEMIC CONTROL
|
POTENTIAL FOR LOSS OF GLYCEMIC CONTROL
|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
ASPIRIN WHEN CONCOMITANTLY ADMINISTERED MAY DECREASE THE METABOLIC CLEARANCE OF NIACIN, NIACINAMIDE & NICOTINAMIDE
|
POTENTIATION OF ORTHOSTATIC HYPOTENSION
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS WITH DRUGS THAT CAUSE MYOPATHY WHEN GIVEN ALONE, SUCH AS LIPID-LOWERING DOSES OF NIACIN ; COMBINED USE SHOULD BE AVOIDED BECAUSE OF INCREASED CHANCES OF MYOPATHY
|